ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2042

Safety and Effectiveness of the Use of Combined Therapy with bDMARDS and tsDMARDs in Immune-mediated Inflammatory Diseases
Abstract Number: 0641

Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease – data from the CASTLE Phase I/II basket study
Abstract Number: 0331

Safety and Efficacy of Colchicine in Osteoarthritis: A Systematic Review and Meta-Analysis of 6,965 Patients
Abstract Number: 0805

Safety and Efficacy of Hydroxychloroquine According to Weight-based Dose: Results of a Global Systematic Review and Meta-analysis
Abstract Number: 2122

Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain
Abstract Number: 0236

Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease
Abstract Number: 2672

Safety and efficacy of Upadacitinib in melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease: a single-centre, retrospective, propensity score-matched cohort study
Abstract Number: 2292

Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
Abstract Number: 1157

Safety and Tolerability of a Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Prospective Longitudinal Study over 12 Months
Abstract Number: 2237

Safety of DMARD therapy in veterans with rheumatoid arthritis following melanoma diagnosis: a survival analysis
Abstract Number: 0453

Safety of DMARDs in Rheumatoid Arthritis: A Nationwide Study of ILD Risk and Outcomes in RA-ILD
Abstract Number: 0257

Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
Abstract Number: 0483

Safety of JAK inhibitors (JAKi) in chronic inflammatory arthritis (CIA): an observational study
Abstract Number: 1434

Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
Abstract Number: 0239

Safety of Rilzabrutinib, a BTK Inhibitor, in Adult Patients with IgG4-related disease (IgG4-RD) in a 52-week Phase 2 Open-label Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].